The MarketReader Minute
💊 Mesoblast Gains on FDA Acceptance, Ionis Down Despite Positive Study Results, Beigene Falls After Announcing New U.S. Facility | Biotech Sector Insights
Medpace Holdings Inc (MEDP) experiencing a notable price decline following its Q2 2024 financial results announcement. The Dow Jones Index (US) also moved -0.17%, potentially impacting IBB given their historical correlation.